{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011949","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.284318+00:00","generated_at":"2026-05-17T07:21:24.560237+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xilio starts Phase 2 XTX301 (IL-12), gets $17.5M milestone from Gilead; cash extended to Q1 2027","bullets":["Initiated patient dosing in Phase 2 of efarindodekin alfa (XTX301) for advanced solid tumors; RP2D selected.","Achieved $17.5M development milestone under Gilead license agreement; expects payment in Q4 2025.","As of June 30, 2025, cash and equivalents $121.6M; plus milestone extends cash runway into Q1 2027.","Phase 1 data: two partial responses (1 confirmed, 1 unconfirmed) in late-line advanced solid tumors; generally well-tolerated.","Gilead can elect to transition development after specified clinical data package for a $75M fee; Xilio eligible for up to $500M in milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011949","json":"https://secwatch.observer/filing/0001558370-25-011949.json","markdown":"https://secwatch.observer/filing/0001558370-25-011949.md","text":"https://secwatch.observer/filing/0001558370-25-011949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025011949/0001558370-25-011949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025011949/xlo-20250909x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:21:24.560237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}